Thus, we asked whether the FDA-approved ponatinib, a more potent RIPK2/MKK7/c-Myc pathway inhibitor than GSK583 and two other commercially available RIPK2-selective inhibitors (Supplementary Fig. 40), can more effectively inhibit metastatic outgrowth. Indeed, ponatinib substantially reduced 22Rv1 ...
As yet, there are no reports of any RIPK3 inhibitor in clinical trials. Interestingly, in a parallel strategy to the development of isoform-specific inhibitors of RIPKs, drug repositioning studies also led to the identification of various FDA-approved drugs as pan-RIPK antagonists, such as ...